NCT00452023 2024-12-11
Pegasys® in Patients With Myeloproliferative Diseases
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
10 trialsNCT04798612 2023-08-18
IPOS
Zealand University Hospital
Phase 2 Unknown
NCT02218164 2022-10-07
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01259817 2017-01-11
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02576964 2016-11-02
A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00241241 2015-10-21
Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
PV-Nord
Phase 2 Completed
NCT01392170 2015-05-04
Pegasys in Patients With Chronic Myeloid Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00227656 2012-12-11
Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00047879 2011-10-26
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00178763 2011-03-03
FR-WB-TT
The University of Texas Health Science Center, Houston
Phase 2 Unknown